1.Analysis of Chinese medicines used in our hospital during 2010-2012
Xinyan LI ; Xiuling ZHANG ; Yongqiao WANG ; Qian DU ; Guangchun SUN
International Journal of Traditional Chinese Medicine 2014;(8):734-736
Objective To analyze the utilization of Chinese medicines in outpatients of our hospital for the rational use of Chinese medicines in clinic. Methods Drug consumption data during 2010-2012 were collected from the hospital information system database,and drug daily dosages(DDDs)and consumption sum were statistically analyzed. Results The amount of Chinese medicines was 33.07%-36.29%of all drugs costs in the outpatients from 2010-2012. From DDDs’top 10 Chinese medicines during 2010-2012, medicine for cardiovascular medications and urinary system had a great percentage, and the doctors used Chinese medicines reasonably. Conclusion The Chinese medicines uses in outpatients of our hospital is generally rational.
2.Study on mutations of exon B~H of the androgen receptor gene in 45 cases of patients with prostate cancer
Xiaohui WANG ; Jian LU ; Xiaoling YU ; Guangchun CHEN ; Jinshan ZHANG ; Yingha SUN
Chinese Journal of Pathophysiology 1986;0(01):-
AIM and METHODS: To learn more about the mechanism of prostate cancer (PC) development and progression to androgen independence, the exons B~H of the androgen receptor (AR) gene of forty-five patients with prostate cancer, six puncture tissues and thirty-nine slide tissues, were analyzed by polymerase chain reaction-single strand conformation technique (PCR-SSCP). RESULTS: Seven abnormal mobility shifts were found in five patients by PCR-SSCP. Combining the method with direct DNA cycle sequencing, two distinct missense (Glu872Gln, Met886Ile) point mutations were identified in puncture tissues from two patients of advanced prostate cancer with distant metastasis. These two point mutations represented two novel mutations. CONCLUSION: AR gene mutations might play an important role in the development and progression of prostate cancer.
3.Percutaneous hepatocholangiostomy in treatment of recurrence hepatobiliary stones
Yanmin LIU ; Kewei ZENG ; Beiwang SUN ; Bin OUYANG ; Huiqing WEN ; Guangchun CHEN ; Ping WANG
Chinese Journal of Postgraduates of Medicine 2006;0(26):-
Objective To explore the potential predominance and value of percutaneous hepatocholangiostomy (PCH) in treatment of recurrence hepatobiliary stones (RHS). Methods Seventeen cases with RHS were treated by PCH from February 2001 to October 2005, which was an improved technology of percutaneous transhepatic cholangioscopy (PTCS) and made reference to the methods of percutaneous nephrostomy (PCN). Results Seventeen cases were successfully treated. The average blood loss was 40 ml (ranging from 15 to 100 ml), and stones were removed completely in 88.2% (15/17). The average hospital stay was 14 (ranging from 10 to 59) days. No one required postoperative analgesic. No postoperative bleeding and biliary leakage were found. Conclusions PCH has significant advantages of minimal invasion, little blood loss, less pain, less complications and quick recovery in the treatment of RHS.
4.Genomics in Neurological Disorders
Han GUANGCHUN ; Sun JIYA ; Wang JIAJIA ; Bai ZHOUXIAN ; Song FUHAI ; Lei HONGXING
Genomics, Proteomics & Bioinformatics 2014;(4):156-164
Neurological disorders comprise a variety of complex diseases in the central nervous system, which can be roughly classified as neurodegenerative diseases and psychiatric disorders. The basic and translational research of neurological disorders has been hindered by the difficulty in accessing the pathological center (i.e., the brain) in live patients. The rapid advancement of sequencing and array technologies has made it possible to investigate the disease mechanism and biomarkers from a systems perspective. In this review, recent progresses in the discovery of novel risk genes, treatment targets and peripheral biomarkers employing genomic technologies will be dis-cussed. Our major focus will be on two of the most heavily investigated neurological disorders, namely Alzheimer’s disease and autism spectrum disorder.